News Releases

OptimizeRx Reports Third Quarter 2017 Results; Net Revenue Up 74% to Record $3.1 Million

November 2, 2017 at 4:00 PM EDT

ROCHESTER, Mich., Nov. 02, 2017 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (OTCQB:OPRX), the nation’s leading provider of digital health messaging via electronic health records (EHRs), reported results for the third quarter ended September 30, 2017. All quarterly comparisons are to the same year-ago quarter.

Q3 2017 Highlights

  • Net revenue increased 74% to a record $3.1 million, driven by growth in financial and brand messaging by new and returning clients.

  • Financial messages, such as eCoupons, and brand messaging were distributed for more than 100 pharmaceutical brands during the quarter.

  • Operating expense as a percentage of revenue improved to 65.4% versus 73.5% in the year-ago quarter.

  • Appointed prominent health IT veteran, Miriam Paramore, as president to drive scale as OptimizeRx offers medication savings at point-of-care.

  • Launched automated financial messaging within iSalus Healthcare’s EHR, alerting health care providers (HCPs) to potential prescription savings and support information for their patients.

  • Added several business development and operations team members to accelerate revenue growth, brand expansion and new product sales.

Q3 2017 Financial Summary
Net revenue in the third quarter of 2017 increased 74% to $3.1 million from $1.8 million in the same year-ago quarter. The increase was primarily due to revenue from OptimizeRx’s two core products of financial and brand messaging coupled with broader distribution with the company’s new channel partners. Additionally, the launch of new pharmaceutical brands, which now totals more than 100 between financial and brand messaging, also contributed to the increase.

Operating expenses in the third quarter of 2017 were $2.0 million, up from $1.3 million in the third quarter of 2016. The increase was primarily due to additional expenses related to growth initiatives, including in the company’s executive and sales team.

Net loss for the third quarter of 2017 was $623,000 or $(0.02) per share, as compared to a net loss of $243,000 or $(0.01) per share in the third quarter of 2016.

Cash and cash equivalents totaled $5.0 million at September 30, 2017, as compared to $5.8 million at June 30, 2017. The company continued to operate debt-free.

Management Commentary

“In Q3, our record topline was driven by the growth of our financial and brand messaging products, as well as the expansion of our EHR network through which those products are distributed to HCPs,” said OptimizeRx CEO, William Febbo. “We added iSalus Healthcare, an industry-leading EHR, to our EHR network, which is still the largest of its kind with more than 370 EHRs nationwide.

“During the quarter, we also continued to see the expansion of clients, brands, and agencies advising the industry about our cloud-based EHR channel. To support further growth and drive scale, we appointed Miriam Paramore, an accomplished health IT industry veteran, as our new president. We also added several business development and operations team members.

“These investments in our executive and sales teams have already begun to produce returns in terms of accelerated revenue growth, broader client base, and greater scale potential. In fact, our operating expenses as a percentage of revenue decreased markedly during the quarter. We see this decrease as demonstrative of the substantial leverage in our operating model, in that it supports greater market reach and revenue growth without the need to incrementally increase operating cost in a matching fashion. So, as we grow, we expect operating expense as a percentage of revenue to continue to decrease.

“Our success in acquiring, integrating and expanding into new promotional EHR/eRx platforms has also continued to strengthen. As a result, we have more master service agreements now than ever before. We recently added Aprima Medical Software, and we are actively engaged in discussions with several additional EHRs to integrate our technology into their platforms. We are also working extensively with our existing platforms to expand the reach of our financial messaging to additional health care providers, as well as increasing the utilization by existing users.

“We believe EHR adoption is here to stay, e-prescription has become well adopted, and point-of-care access is proving highly valuable to pharma. All of this is conducive to the growth of our unique marketing channel between pharma companies and HCPs. We also believe we have only just begun to scratch the surface of our market potential. So, with the growth of pharma brands, channel partners and HCPs on our EHR network, we expect the distribution of our financial messaging will continue to increase, and our brand messaging will continue to support top-line growth.

“For the remainder of the year and beyond, we will remain focused on engaging more brands, and developing more solutions and more reach. Given the greater visibility into our expanding client base, we believe we are well on track for another record quarter ahead.”

Conference Call
OptimizeRx management will host the presentation, followed by a question and answer period.

Date: Thursday, November 2, 2017
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Toll-free dial-in number: 1-800-406-5345
International dial-in number: 1-719-457-2644
Conference ID: 4446715

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact CMA at 1-949-432-7566.

A replay of the call will be available after 7:30 p.m. Eastern time on the same day through November 23, 2017, as well as available for replay via the Investors section of the OptimizeRx website at

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 4446715

About OptimizeRx
OptimizeRx® (OTCQB:OPRX) is the nation’s leading provider of digital health messaging via electronic health records (EHRs). The company’s cloud-based solution supports patient adherence to medications by providing convenient access to financial assistance, prior authorization, education, and critical clinical information. The company’s network is comprised of more than 370 independent EHR platforms, providing more than half a million healthcare providers access to these benefits within their e-prescribing workflow and at the point of care. The largest of its kind, the OptimizeRx EHR network helps improve patient care and outcomes by providing a direct channel for pharma companies to communicate with healthcare providers. For more information, follow the company on Twitter, LinkedIn or visit  

Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

    September 30,
    December 31,
Current Assets            
Cash and cash equivalents   $ 5,013,128     $ 7,034,647  
Accounts receivable     2,704,752       3,060,396  
Prepaid expenses     246,806       80,820  
Total Current Assets     7,964,686       10,175,863  
Property and equipment, net     180,459       173,649  
Other Assets                
Patent rights, net     721,476       772,394  
Web development and other intangible costs, net     942,972       351,804  
Security deposit     5,049       5,049  
Total Other Assets     1,669,497       1,129,247  
TOTAL ASSETS   $ 9,814,642     $ 11,478,759  
Current Liabilities                
Accounts payable – trade   $ 720,758     $ 369,214  
Accrued expenses     434,559       288,268  
Revenue share payable     1,877,991       2,622,517  
Deferred revenue     729,092       386,581  
Total Liabilities     3,762,400       3,666,580  
Stockholders’ Equity                
Preferred stock, $.001 par value, 10,000,000 shares authorized, no shares issued and outstanding     -       -  
Common stock, $.001 par value, 500,000,000 shares authorized, 29,275,117 and 29,718,867 shares issued and outstanding, respectively     29,275       29,719  
Stock warrants     2,294,416       2,294,416  
Additional paid-in-capital     33,854,614       33,747,137  
Accumulated deficit     (30,126,063 )     (28,259,093 )
Total Stockholders’ Equity     6,052,242       7,812,179  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 9,814,642     $ 11,478,759  

    For the Three Months Ended     For the Nine Months Ended  
    September 30     September 30  
    2017     2016     2017     2016  
NET REVENUE   $ 3,102,607     $ 1,786,137     $ 8,120,502     $ 5,458,944  
REVENUE SHARE EXPENSE     1,703,676       723,396       4,690,943       2,539,021  
GROSS MARGIN     1,398,931       1,062,741       3,429,559       2,919,923  
OPERATING EXPENSES     2,028,589       1,311,959       5,320,220       4,133,505  
LOSS FROM OPERATIONS     (629,658 )     (249,218 )     (1,890,661 )     (1,213,582 )
OTHER INCOME (EXPENSE)                                
Interest income     6,872       6,634       23,691       27,292  
Interest expense     -       -       -       (163 )
TOTAL OTHER INCOME (EXPENSE)     6,872       6,634       23,691       27,129  
LOSS BEFORE PROVISION FOR INCOME TAXES     (622,786 )     (242,584 )     (1,866,970 )     (1,186,453 )
PROVISION FOR INCOME TAXES     -       -       -       -  
NET LOSS   $ (622,786 )   $ (242,584 )   $ (1,866,970 )   $ (1,186,453 )
BASIC AND DILUTED     29,256,367       29,433,846       29,517,975       29,374,319  
NET LOSS PER SHARE                                
BASIC AND DILUTED   $ (0.02 )   $ (0.01 )   $ (0.06 )   $ (0.04 )

OptimizeRx Contact:
Doug Baker, CFO
Tel (248) 651-6568 x807

Investor Relations Contact
Ron Both, CMA
Tel (949) 432-7557

Source: OptimizeRx Corporation